DRG SARS-CoV-2 (RBD) Total Ab ELISA
SARS-CoV-2 (RBD) Total Ab ELISA
ELISA for the qualitative and highly sensitive detection of total (IgA, IgM and IgG) antibodies against Coronavirus SARS-CoV-2 in serum and plasma.
Benefits at a Glance:
- Tests detect neutralizing antibodies directed against Receptor Binding
- Domain (RBD) of spike protein of SARS-CoV-2 High specificity and sensitivity Results in 75 (Total Ab) minutes
- Ready-to-use reagents included
- Tests are prepared for automation on open ELISA platforms
- Developed, validated and manufactured in Marburg, Germany
- EU: CE / IVD
Intended Use of DRG SARS-CoV-2 Antibody ELISAs
SARS-CoV-2 (RBD) Total Ab (EIA-6154); qualitative
- Sensitive detection of prior virus infection (> 14 days after infection)
- Support of diagnosis of COVID-19 disease, supplement of direct pathogen detection via RT-PCR or pulmonary CT-Scans
- Support epidemiological studies for SARS-CoV-2
- Monitor vaccination success
The DRG SARS-CoV-2 (RBD) total Ab ELISA is an enzyme immunoassay for the qualitative in vitro diagnostic measurement of IgG/IgM/IgA antibodies to SARS-CoV-2 in serum and plasma (EDTA, Li-heparin or citrate).
This specific ELISA is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. It can support the diagnosis of COVID-19 disease and supplement direct pathogen detection via RT-PCR or pulmonary CT-Scans. In addition, serology can help to gather epidemiological information on the disease prevalence.